Cytogen, Inc. (KOSDAQ:217330)
South Korea · Delayed Price · Currency is KRW 2,925.00
-145.00 (-4.72%)
At close: Oct 29, 2025
Cytogen Company Description
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea.
The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies.
The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.
Cytogen, Inc.
| Country | South Korea |
| Founded | 2010 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 42 |
| CEO | Byung-Hee Jeon |
Contact Details
Address: SK V1 GL Metrocity Seoul, 05854 South Korea | |
| Phone | 82 2 6925 1070 |
| Website | cytogenlab.com |
Stock Details
| Ticker Symbol | 217330 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Byung-Hee Jeon | Chief Executive Officer |